Nakaya Matsumaru, General Manager of Catalent Minakuchi
Nick brings a great deal of experience, and will play an important role in the ongoing expansion of Catalent’s Asia-Pacific network and ensuring that customers’ clinical trials continue to be well-served across the region, and worldwide
SOMERSET, N.J. (PRWEB)
December 10, 2020
Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced the appointment of Nakaya “Nick” Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.
Reporting to Roel de Nobel, Catalent’s Vice President of Operations for Europe and Asia-Pacific, Mr. Matsumaru joins the company from SymBio Pharmaceuticals Ltd, where he held the role of Senior Director Supply Chain & Quality Assurance. Prior to this, he spent four years in vice president, executive officer and head of operations posts with AstraZeneca, and seven years in Japan-based supply chain management with Johnson & Johnson and Janssen. He holds a bachelor’s degree in sociology from Keio University in Tokyo.
“We are pleased to welcome Nick to head our clinical supplies business at our new facility in Shiga, which in partnership with our existing Japanese facility in Kakegawa, will provide flexible clinical supply solutions to customers in Japan and global biotech and pharmaceutical companies,” commented Mr. de Nobel. He added, “Nick brings a great deal of experience, and will play an important role in the ongoing expansion of Catalent’s Asia-Pacific network and ensuring that customers’ clinical trials continue to be well-served across the region, and worldwide.”
Catalent announced it had completed the acquisition of the 60,000-square-foot facility in Shiga from Teva-Takeda Pharmaceuticals in July 2020. The facility is the latest in Catalent’s expanding Asia-Pacific clinical supplies network, and alongside the existing Japanese facility in Kakegawa, the company’s two sites in China and one in Singapore, will offer extensive services including access to primary and secondary packaging capabilities, Catalent’s FastChain® demand-led supply services, a range of temperature options for storage and distribution, as well as clinical returns and destruction services.
About Catalent Clinical Supply Services
Catalent is a global leader in clinical supply services, with comprehensive and flexible solutions for small molecules, biologics, and cell and gene therapies and integrated solutions to accelerate speed to clinic. Catalent offers a full range services including clinical supply management, comprehensive packaging solutions, comparator sourcing, cold chain storage and global distribution and specialized supply chain services including direct-to-patient and demand-led supply. With nine GMP clinical packaging facilities and over 50 strategically located depots on six continents combined with more than 25 years’ experience across thousands of studies in more than 80 countries, Catalent has the comprehensive services, global scale and expertise necessary to reliably supply clinical trials of all sizes and complexity anywhere in the world.
About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs approximately 14,000 people, including around 2,400 scientists and technicians, at more than 45 facilities, and in fiscal year 2020 generated over $3 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com
More products. Better treatments. Reliably supplied.™
Share article on social media or email: